WHO-led trial to study three anti-inflammatory drugs for COVID-19 patients

Ipca Laboratories

11/08/2021 12:51

ZURICH, Aug 11 (Reuters) - The World Health Organization on
Wednesday said a clinical trial in 52 countries will study three
anti-inflammatory drugs as potential treatments for COVID-19
patients.
    "These therapies - artesunate, imatinib and infliximab –
were selected by an independent expert panel for their potential
in reducing the risk of death in hospitalised COVID-19
patients," it said in a statement.
    Artesunate is already used for severe malaria, imatinib for
certain cancers, and infliximab for diseases of the immune
system such as Crohn's Disease and rheumatoid arthritis.

 (Reporting by Michael Shields; editing by Jason Neely)
 ((Michael.Shields@thomsonreuters.com; +41 41 528 3630; Reuters
Messaging: michael.shields.thomsonreuters.com@reuters.net))